Our Research

Basic Research Activities

  • Application of Bioinformatics in the area of Psychoneuroimmunology
  • Ongoing
  • Development of Blot method for Anti Proteus mirabilis antibodies
  • Development of Simple Method to Detect Malarial Parasites Invitro from Whole Blood.
  • Genetic /DNA Analysis of Family with RA Its Relationship and Rheumatoid Factor
  • Incidence of Anti-CCP, Rheumatoid Factor in first degree relatives of Rheumatoid Arthritis Patients

Clinical Trial Projects

S.NO Clinical Trial Projects Title Year Study Period Recruitment Status Study On
1 A Multicenter, Randomized, Double – Blind, Placebo controlled trials of Golimumab, a Fully Human Anti-TNF a Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve subjects with Active Rheumatoid Arthritis 2006 ONGOING 5 Year CLOSED RA
2 A Randomized, Open label, Four Arms Parallel Study to Evaluate the Safety and Efficacy of anti-CD6 monoclonal antibody (T1hMAb) in Combination with B9
CTRI No.and Date CTRI/2008/091/000295, 22-12-2008
UTRN.WHO TEMP UTRN 110159200-19122008397753
2006 COMPLETED 1 Year CLOSED RA
3 Double-blind, triple dummy, parallel-group, randomized, six month study to compare Celecoxib (200 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events. Protocol A3191084" from the sponsor company Pfizer Limited. 2007 COMPLETED 6 Months CLOSED RA
4 A phase II, randomized, double-blind, placebo-controlled, Parallel- group study to assess the safety and efficacy of Maraviroc (uk-427,857) in the treatment of rheumatoid Arthritis in subjects receiving Methotrexate for protocol No A4001056 2006 COMPLETED 2 YEARS CLOSED RA
5 A Phase IIIB, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to compare the efficacy and safety of Abatacept administered Subcutaneously and Intravenously in subjects with Rheumatoid Arthritis, receiving background Methotrexate, and experiencing an Inadequate response to Methotrexate. 2006 ONGOING 3 YEARS CLOSED RA
6 A Multicenter, randomized, double blind, placebo controlled study, comparing the efficacy and safety of BioCell Collagen II ® 1000 mg twice daily as compared with glucosamine sulfate 750 mg twice daily, biofermented hyaluronic acid 100 mg twice daily, glucosamine HCL 750 mg + chondroitin sulfate 600 mg twice daily and placebo twice daily in subjects with osteoarthritis. 2008 ONGOING 3 YEARS CLOSED RA
7 Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80mg, 160mg, and 320mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate – ALD518-CLIN-003. 2007 COMPLETED 3 YEARS CLOSED RA
8 A Multi-Center, Randomized, Double -Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Uprate Lowering Therapy. 2008 ONGOING 3 YEARS CLOSED RA
9 A Multi-Center, Randomized, Double -Blind, Placebo Controlled Trial of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy. 2008 ONGOING 3 YEARS CLOSED RA
10 Study Title: An open label, non-comparative study to evaluate the efficacy, safety, and tolerability of Lornoxicam 8 mg tablet in the treatment of Rheumatoid Arthritis.
CTRI No.and Date CTRI/2009/091/000297, 24-07-2009 UTRN.WHO TEMP UTRN 030232938-200520097411059
2009 ONGOING 3 YEARS CLOSED RA
11 Multi-National Open-Label Study to Evaluate the safety, Tolerability and efficacy of Tocilizumab in patients with Active Rheumatoid Arthritis on background Non-biologic DMARDs who have an Inadequate Response to current Non-biologic DMARD and/or Anti TNF Therapy 2009 COMPLETED 3 YEARS CLOSED RA
12 A Phase IIA, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012When Given with Methotrexate to Subjects With Active Rheumatoid Arthritis who have had an Inadequate response to Conventional Disease Modifying Anti-rheumatic drug therapy CTRI/2009/091/000642, 27-08-2009 TEMP UTRN 102429886-120820091108970 2008 COMPLETED 3 YEARS CLOSED RA
13 A Phase III , Multi-center, randomized double blind, controlled study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with non-steroidal anti-inflammatory drugs(NSAIDs)versus NSAIDs alone in patients with osteoarthritis of the knee or hip. CTRI/2009/091/000405, 25-06-2009 TEMP UTRN 064015006-190620098621180 2009 ONGOING 3 YEARS CLOSED RA
14 A multicenter, phase III, single arm, open label trial of the efficacy and safety of certolizumab pegol given subcutaneously as an adjunctive medication to methotrexate in the treatment of rheumatoid arthritis in Indian subjects who have an inadequate response to methotrexate 2007 COMPLETED 2 YEARS CLOSED RA
15 "Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis on Background Methotrexate UTRN.WHO TEMP UTRN 113817210-2807200910601180 CTRI No.and Date CTRI/2009/091/000596, 29-07-2009 2008 APPROVED 2 YEARS CLOSED RA
16 A Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821, (an Anti-IL-17Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy. CTRI/2009/091/000777, 11-01-2010 TEMP UTRN 114017134-1709200912531078. 2009 ONGOING 1 YEAR CLOSED RA
17 Long terms, open label, follow up study of CP690-550. A Moderately selective Janus-Kinase-3 inhibitor for treatment of Rheumatoid Arthritis. 2010 ONGOING 2 YEARS CLOSED RA
18 An Open label, prospective, non-comparative, multicentre study to assess the safety and efficacy of Etanarcept for injection 25mg in patients with moderate to severe active rheumatoid arthritis. 2009 ONGOING 6 MONTHS CLOSED RA
19 A Prospective Observational Study to Evaluate Long-Term Safety and Functional Status of Subjects with Rheumatoid Arthritis Previously Enrolled in Studies of CP-690,550". 2010 ONGOING 2 YEARS ONGOING RA
20 Cytokine in Tuberculosis and contacts can it predict the outcome? 2010 APPROVED 6 MONTHS ONGOING RA
21 A study to ascertain the population prevalance of Rheumatic diseases in Bangalore Urban area. 2010 APPROVED 6 MONTHS ONGOING RA
22 D4300C00002 : (OSKIRA-2): Multi-Centre, Randomised, Double Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs 2010 APPROVED 1 YEAR ONGOING RA
23 (OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis 2010 APPROVED 1 YEAR ONGOING RA
24 NA22823 B: A phase II/III seamless, multicentre, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with Tocilizumab versus placebo in patients with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naive to TNF antagonist theraphy 2010 APPROVAL AWAITED 5 YEARS ONGOING RA
25 14V-MC-JADA A randomized, double-blind, placebo-controlled, dose-ranging , parallel-group, phase 2b study of LY 3009104 in patients with Active Rheumatoid Arthritis on background Methotrexate theraphy 2010 APPROVED 6 MONTHS ONGOING RA
26 An Open-label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-modifying Antirheumatic Drug (DMARD) Therapy in Biologic-naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2) CTRI No.and Date CTRI/2009/091/000883, 23-11-2010 UTRN.WHO TEMP UTRN 061615108-271020091367923 2010 APPROVED 1 YEAR CLOSED RA
27 GP13,-201"A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficicacy of GP13-201 and rituximab in patients with rheumatoid arthritis refractory or intolerant to standard DMARDs and one or two anti-TNF therapies" IN THE PIPELINE 2010 1 YEAR YET TO BE APPROVED RA